Citi lowered the firm’s price target on Baxter to $37 from $38 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the U.S. medical technology space. While Citi anticipates that investors will “continue to lean into quality names that have consistently beat and raised,” with the significant reset in valuations across the group there is “opportunity across the cap stack,” the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter call volume above normal and directionally bullish
- Baxter up 5% after WSJ report on Carlyle talks to buy kidney care unit
- Carlyle in talks to buy Baxter’s Vantive business for over $4B, WSJ reports
- Carlyle in advanced talks to buy Baxter’s Vantive business, WSJ reports
- Baxter price target lowered to $45 from $46 at Evercore ISI
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue